Biogen revenue leaps 50% on blockbuster-level Tecfidera sales

Tracy Staton Launched last April, Tecfidera racked up more than a half-billion dollars in sales for the first quarter of this year. That puts its cumulative total at $ 1.38 billion–well ...

Gilead’s Sovaldi turns in outsize Q1 sales

Eric Palmer Powered by sales that averaged more than $ 25 million a day for brand-new hep C drug Sovaldi, Gilead Sciences beat all expectations, with quarterly sales that nearly doubled ...

Gardasil dose reduction could boost EU sales for Merck-Sanofi joint venture

Tracy Staton Now that the European Commission has officially approved a two-dose Gardasil regimen for early teens, Merck and Sanofi–who market the HPV vaccine in Europe through ...

Doxycycline sales power Hikma, but party may be ending

Eric Palmer Jordan-based Hikma has powered its growth with drugs on the FDA's shortage list such as doxycycline, sales of which have allowed the company to raise earnings projections ...

Busy Regeneron busts Eylea sales forecasts, re-ups with Sanofi

Tracy Staton Yesterday, Regeneron CEO Len Schleifer announced that rather than the $ 377 million expected by analysts, Regeneron will report about $ 400 million in U.S. sales for macular ...

Celgene looks to double its sales by 2017 on wave of cancer drug growth

Tracy Staton Celgene figures it will end 2014 with $ 7.4 billion in net sales, adding about $ 1 billion to its $ 6.4 billion total for 2013. But by 2017, the company figures it will ...

Merck is cutting 150 in its Saphris sales team after selling the drug to Forest for $240M

Eric Palmer Merck early in December agreed to sell the rights to its antipsychotic drug Saphris to Forest Laboratories for $ 240 million. The move not only gave it a small cash boost, ...

Eisai to cut R&D, even as it boosts its sales operation

Eric Palmer Japanese drugmaker Eisai is cutting its R&D operations, with plans to eliminate 130 positions from its facility in Andover, MA, as well as other research centers ...

Actavis cutting 30% of U.S. sales organization

Eric Palmer Actavis began tallying up just how many bodies it needed in its U.S. sales organization as soon as it closed Oct. 1 on its $ 8.5 billion merger with Warner Chilcott.  FiercePharma ...

Merck’s next-gen HPV vaccine looks good in PhIII, but sales may disappoint

John Carroll Merck believes it can win near-term approval for a new HPV vaccine that will do better than Gardasil in guarding women against the virus that causes cervical cancer. But ...

Once again, Bayer’s new drugs power pharma sales upward

Carly Helfand Eye drug Eylea and blood thinner Xarelto are pretty good products for any drugmaker to have in its lineup, and Bayer's got them both. Sales of those new stars have ...

FDA bans suck sales out of Ranbaxy, Wockhardt

Eric Palmer Import bans imposed against two of India's largest generic drugmakers are already shaving away their financial performance, even though the worst is yet to come. Both ...
Page 3 of 912345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS